Scalper1 News
Valeant Pharmaceuticals reported a mixed first quarter Thursday, a busy day for drugmakers’ earnings reports. The Canadian drugmaker reported earnings of $1.76 a share, up 35% from the year-earlier quarter and beating by 4 cents the consensus of analysts polled by Thomson Reuters. Sales rose 77% to $1.89 billion, short of consensus for $1.97 billion. Shares fell nearly 2% to 131.17. Valeant (VRX) did not issue new guidance, as it had Scalper1 News
Scalper1 News